The big one that stands out to me is the P&L.
GPT P&L is still understandable to me - they are expecting to make just short of 500m dollars... thats after paying their 250m interest, so they have a further 2x+ coverage up their sleeve.
However CNP declared 185m profit and proceeded to make an accounting adjustment of 1.3bn odd on the P&L -resulting in a net loss of 1.1bn odd.
GPT MAT ratios and other KPIs also seem to be significantly healthier- I suspect reflecting better quality of management of assets.
And at a glance, GPT has a strongly performing existing asset base that underpins its earnings (516m in Australian property leases) - CNP appeared to be much more reliant on development projects - IE things that hadn't been complete yet, or not come online yet, or perhaps wouldn't be worth / yield a much as originally expected.
But it really only was a glance - and its tempered with things I "hope" rather than "know".
- Forums
- ASX - By Stock
- GPT
- why gpt is not the new centro
GPT
gpt group
Add to My Watchlist
0.79%
!
$5.10

why gpt is not the new centro, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.10 |
Change
0.040(0.79%) |
Mkt cap ! $9.769B |
Open | High | Low | Value | Volume |
$5.06 | $5.13 | $5.06 | $33.90M | 6.648M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4468 | $5.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.13 | 4468 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 5.070 |
1 | 180 | 5.050 |
1 | 100 | 5.010 |
1 | 200 | 4.950 |
1 | 3093 | 4.940 |
Price($) | Vol. | No. |
---|---|---|
5.140 | 1100 | 1 |
5.150 | 146286 | 6 |
5.170 | 426 | 1 |
5.180 | 700 | 1 |
5.190 | 378 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
GPT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online